Astellas

News

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

News

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

Oncology

Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.

News

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.

News

Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.

Sales & Marketing

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.